K14-VEGF-C transgenic mice display greater inflammatory cell migration and faster resolution of inflammation. (A) Coimmunostaining of LYVE-1 and CD31 in whole mounted (top panels) and sectioned (middle panels) ear skin and paracortical regions of sectioned DLNs (bottom panels) in K14-VEGF-C (K14-VC) and wild-type mice. Scale bars represent 50 μm. (B) FITC-conjugated dextran (3 μL) was intradermally injected into the ear skin (○), and 5 minutes later the distribution of FITC was visualized by a fluorescence stereomicroscope. Bottom panels show higher magnifications. (C,D) At day 3 after the injection of LPS, 3 μL FITC-conjugated dextran was intradermally injected into the inflamed skin. Fluorescence intensities were determined in DLNs at 30 minutes after the injection using IVIS, quantified, and presented as relative radiance (photon/sec per cm²/steradian). (E,F) At day 3 after intradermal injection of LPS, the GFP⁺ inflammatory cells (∼ 10⁶ cells) were injected intradermally into the inflamed skin. Twelve hours later, the DLNs were sectioned and immunostained for LYVE-1. Scale bars represent 50 μm. The GFP⁺ inflammatory cells in the DLNs were quantified and presented as AU. (G,H) At day 6 after intradermal injection of LPS, ears were photographed, and the severities of erythema and swelling were scored. All bars represent mean ± SD from 4 to 5 mice. *P < .05 versus wild type. (I,J) At days 0, 1, and 3 after the injection of FITC-LPS, the remaining FITC-LPS was quantified using IVIS and presented as relative radiance (photons/sec per cm²/steradian). All dots represent mean ± SD from 4 to 5 mice. *P < .05 versus wild type; ^#P < .05 versus LPS in wild type.